Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Choline Chloride for Injection in Intestinal Failure
NCT06910943Phase 3Recruiting
- Sponsor
- Protara Therapeutics
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of choline chloride in choline deficiency disease and Liver injury (8 arms), sponsored by Protara Therapeutics. Primary endpoints: Maximum Plasma Concentration of Free Choline at Week 8, Time to Maximum Plasma Concentration of Free Choline at Week 8 and 5 more. Started Dec 2025; status: recruiting.
02
Drugs
choline chloride
03
Conditions
choline deficiency diseaseLiver injury
Beyond the preview
Go deeper on NCT06910943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06910943.